证券日报网讯爱朋医疗10月17日发布公告，在公司回答调研者提问时表示，公司围术期脑状态监测产品 麻醉深度监护仪已获得3张注册证，完成20多个省份的挂网并产生销售。公司全新推出的顽固性失眠麻 醉治疗系统，目前已落地医院开展临床治疗，商业化正式开始推广，其收费主要根据实际的治疗项目对 应收费。公司近期获取的两款脑电采集产品医疗器械注册证是公司"多模态ADHD行为治疗管理系统"的 核心组成部分，目前公司已经和复旦大学附属儿科医院共同成立脑机接口行为治疗联合实验室，将科研 创新与临床场景紧密结合，为ADHD儿童提供全新认知行为治疗解决方案。ADHD行为治疗在院内是有 相应的收费目录的，同时湖北、浙江、江苏等地相继出台脑机接口相关医疗服务价格项目，其中非侵入 式脑机接口适配费966元/次。9月24日国家医保局出台新规，明确将为脑机接口等创新医疗产品开通医 保赋码"绿色通道"，为脑机接口临床实践及应用提速。 （文章来源：证券日报） ...

Core Insights - The company Aipeng Medical has received three registration certificates for its perioperative brain state monitoring product, the anesthesia depth monitor, and has completed network access in over 20 provinces, generating sales [1] - A new treatment system for refractory insomnia has been launched and is currently undergoing clinical treatment in hospitals, with commercialization efforts initiated based on actual treatment project execution [1] - The company has established a joint laboratory for brain-machine interface behavioral therapy in collaboration with the Children's Hospital affiliated with Fudan University, focusing on cognitive behavioral therapy for children with ADHD [1] - The core component of the multimodal ADHD behavioral management system has received registration certification, and non-invasive brain-machine interface adaptation fees have been set at 966 yuan per session in regions such as Hubei, Zhejiang, and Jiangsu [1] - The National Medical Insurance Administration has opened a "green channel" for innovative products like brain-machine interfaces, facilitating the acceleration of clinical application [1]

Group 1: Company Overview - Aipeng Medical focuses on medical devices, particularly in pain management and nasal airway management, while also exploring brain-computer interface innovations [4] - The company has established a partnership with Ruishen'an Medical, a leading player in the domestic neuroregulation field [4] Group 2: Product Development and Market Position - The company has launched a perioperative brain state monitoring product, which has received 3 registration certificates and is generating sales across over 20 provinces [5] - The newly introduced treatment system for refractory insomnia has begun clinical applications, with pricing based on specific treatment projects [5] - The non-invasive brain-computer interface adaptation fee is set at 966 RMB per session, with recent regulations facilitating insurance coverage for innovative medical products [5] Group 3: Technological Advancements - The anesthesia depth monitoring device utilizes a proprietary index, collecting EEG data at 2,000 times per second, providing a comprehensive analysis of anesthesia depth [8] - The company’s new generation ADM series anesthesia depth monitor offers enhanced performance, usability, and stability, with features including EEG spectrum analysis and anesthesia depth assessment [8] Group 4: Strategic Collaborations - Aipeng Medical's investment in Ruishen'an in 2019 was driven by strategic synergies in chronic pain treatment, particularly with the development of implantable vagus nerve stimulators [9][10] - The collaboration has expanded to include various products for epilepsy and pain management, achieving significant sales [10] Group 5: Future Research and Development Plans - The company aims to deepen research in sensors, electrodes, and EEG signal processing, focusing on clinical applications for sleep disorders, ADHD, and epilepsy [11] - An Artificial Intelligence and Brain-Computer Engineering Research Institute has been established to drive innovation in pain management, anesthesia, and mental health treatment [11]